AstraZeneca Group News

It must be disappointing to know that a label change on another drug -- one that isn't even your competition -- is going to hurt A sales, but that's the position that Procter & Gamble and AstraZeneca find themselves in.

The United States Court of Appeals for the First Circuit upheld an earlier District Court ruling yesterday, approving a settlement in the long-running Average Wholesale Price pharmaceutical litigation against AstraZeneca Pharmaceuticals .

A local nonprofit drug assistance program will expand to give more uninsured Tennesseans access to critical medications at a time when many prescriptions are 9 percent more costly than they were a year ago.

On 11/19/09, AstraZeneca announced the submission of a New Drug Application to the FDA for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome .

The drug, which if approved by the US Food and Drug Administration will be sold under the brand Brilinta, is an investigational oral anti-platelet treatment of acute coronary syndrome .

AstraZeneca PLC said Thursday it has applied to U.S. regulators to market its blood clot preventer Brilinta, a potential new big seller for the company.

AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor ) at the annual American Heart Association Scientific Sessions in Orlando, FL,with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation .

The Medicines Co. , which six months ago stopped two likely-to-fail Phase III trials of antiplatelet drug cangrelor , is out to prove its frog of a drug may be a prince after all.

Has the tide turned against states in their drug pricing suits against Big Pharma? Last month, we reported on a landmark ruling from the Alabama Supreme Court that threw out more than $270 million in verdicts against Novartis, GlaxoSmithKline and AstraZeneca, which had been found liable for overcharging the state Medicaid system for drugs.

AstraZeneca today announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome patients, those with ST Segment Elevation Myocardial Infarction .

Heart attack patients in need of emergency procedures were less likely to suffer further serious cardiovascular events, including death, when given AstraZeneca's experimental Brilinta blood clot preventer than those who used Plavix, according to a study presented on Sunday.

Of the companies that make the vaccine for the swine flu, only one has avoided the production problems caused by a slow-growing virus strain.

Nov. 13 -- David Brennan, chief executive officer of AstraZeneca Plc, speaks about proposals to overhaul the U.S. health-care system.

The CEO of one of the biggest pharmaceutical companies in the country said on Friday that he and others in the industry would switch their support for health care reform to opposition if Congress settles on legislation passed by the House of Representatives.

Eli Lilly & Co. said Friday its science and technology head will retire and that it has hired the chief researcher at AstraZeneca PLC to replace him.

After all, Wikipedia has become a lot of people's source of choice, at least as a starting point for further research.

Main Category: Caregivers / Homecare Also Included In: Seniors / Aging ; Psychology / Psychiatry Article Date: 12 Nov 2009 - 4:00 PST printer friendly view / write opinions rate article ProPublica / The Chicago Tribune examine the case of a controversial psychiatrist who delivered an anti-psychotic medication to thousands of Medicaid patients in ...

On one hand, Chicago psychiatrist Dr. Michael Reinstein was bringing the company a small fortune in sales and was conducting research that made one of its most promising drugs look spectacular.

Simcere Pharmaceutical Group has reached an agreement to acquire the manufacturing license of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd.

Investors who are bullish on the generic drug industry may consider implementing a 130 / 30 global pharma investing strategy through equal-weight short positions for the six brand drug companies outlined below with 30% of their assets while investing 130% of assets in long positions among generic drug makers.